Answers are grounded in this paper and cite their sources.
Reveals tRNA-derived fragment AS-tDR-008272 increases glycolysis and tumor growth in NSCLC, suggesting new therapeutic possibilities.
Background Increasing reports have highlighted the roles of tRNA-derived fragments (tRFs) in the pathological processes of cancers. However, the biogenesis, precise functions, and underlying mechanisms of tRFs in non-small-cell lung cancer (NSCLC) remain largely unexplored. Methods Dysregulated tRFs in NSCLC were identified by tRF & tiRNA sequencing, qRT-PCR, and fluorescence in situ hybridization (FISH) assays. The biological roles of tRF in cell malignant phenotypes and aerobic glycolysis were determined by functional experiments in vitro and in vivo. The clinical significance of tRF was assessed in human NSCLC samples using FISH and 18 F-FDG PET/CT scan. The underlying mechanisms of tRF were explored by RNA sequencing, dual-luciferase assay, polysome profiling, Western blotting, qRT-PCR, and rescue experiments. Results We identified a novel tRF, AS-tDR-008,272, which was upregulated in NSCLC tumor tissues, plasma, and in NSCLC cells. We revealed that the biogenesis of AS-tDR-008,272 was induced by angiogenin (ANG) under hypoxic conditions. Functional assays indicated that AS-tDR-008,272 promoted proliferation, migration, and glycolysis metabolism capacities of NSCLC cells. While inhibition of AS-tDR-008,272 suppressed NSCLC cell growth in vitro and in vivo. Clinically, higher expression of AS-tDR-008,272 in NSCLC tumor tissues was associated with advanced TNM stage, poorer survival, and SUVmax of 18 F-FDG PET/CT scan in NSCLC patients. Mechanistically, AS-tDR-008,272 enhanced NSCLC cell malignancy by interacting with HJURP through a dual regulatory mechanism: binding to the coding sequence (CDS) of HJURP mRNA to regulate its transcription and enhancing the abundance of HJURP mRNA in polysomes to promote its translation. Conclusions Our findings reveal a previously unrecognized tRF-mediated glycolysis reprogramming mechanism in NSCLC tumorigenesis. AS-tDR-008,272 may represent a promising prognostic marker and therapeutic target for NSCLC.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: